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Background: Long-term right ventricular apical (RVA) pacing increases the risk of heart failure (HF) by
inducing ventricular dyssynchronization. Although recent studies suggest that right ventricular septal
(RVS) pacing results in improved short-term outcomes, its long-term effectiveness remains unclear.
Methods and results: This study investigated 149 consecutive patients who underwent implantation of
a dual chamber pacemaker for atrioventricular block with either RVS-pacing between July 2007 and
June 2010 or RVA-pacing between January 2003 and June 2007. The endpoint was deﬁned as death and
hospitalization due to heart failure (HF). The rates of mortality and hospitalization due to HF were
signiﬁcantly lower in the RVS-pacing group than that in the RVA-pacing group (event free RVS: 1 year,
98% and 2 years, 98%; RVA: 1 year, 85% and 2 years, 81%; po0.05). None of the patients died from HF in
the RVS-pacing group, while 4 patients died from HF in the RVA-pacing group within 2 years after
pacemaker implantation. The paced QRS interval was signiﬁcantly shorter with RVS pacing than with
RVA pacing at different times after pacemaker implantation (RVS: immediately 157.8724.0 ms, after
3 months 157.3717.5 ms, after 6 months 153.6721.7 ms, after 12 months 153.6719.4 ms, after 24
months 149.3724.0 ms vs. RVA: immediately 168.3723.7 ms, after 3 months 168.7726.0 ms, after
6 months 168.0722.8 ms, after 12 months 171.2722.3 ms, after 24 months 176.1725.5 ms;
po0.05).
Conclusions: RVS pacing is feasible and safe with more favorable clinical beneﬁts than RVA pacing.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Right ventricular apical (RVA) pacing can result in ventricular
dyssynchrony and decreased ejection fraction (EF), thereby lead-
ing to increased hospitalizations and mortality [1–4]. In contrast,
pacing at the right septum and right ventricular outﬂow tract
(RVOT) may result in more physiologic pacing [5]. While echo-
cardiographic studies suggest that right ventricular septal (RVS)
pacing can improve short-term outcomes and left ventricular
systolic performance [6–8], there is no deﬁnitive evidence that
RVS pacing is superior to RVA pacing in the long term. This may
be because there is no consistency in lead placement among
studies. Most studies are potentially ﬂawed in that the leads were
positioned in the RVOT and not necessarily in the septal position
[6,7–11]. Furthermore, many short-term studies have reported art Rhythm Society. Published by E
rtment of Internal Medicine,
ai, Shinagawa-ku,
kuchi).physiologic beneﬁt of RVS pacing, and the negative remodeling
effect of RVA pacing can take a year or more to manifest in
patients with previously normal or near-normal ventricles. Some
studies have investigated the long-term effect of RVS pacing, but
the duration of follow-up was limited to 18 months, and the
patient population included patients with atrial ﬁbrillation or
patients with ventricular pacing. Another reason for the reluc-
tance to accept RVS pacing among physicians may be their
concerns regarding long-term lead performance (e.g., R-wave
sensing, stimulation threshold, and impedance) and complica-
tions. Thus, the goal of this study is to compare the long-term
effectiveness of RVS pacing vs. RVA pacing in patients with
atrioventricular block.2. Methods
This observational study was performed at Showa University
Hospital. Subjects included patients with second-degree or
higher-degree atrioventricular block who exhibited clinical symp-
toms accompanied by bradycardia. All patients underwentlsevier B.V. All rights reserved.
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secutive patients with RVS lead implantation were considered
eligible for study participation from July 2007 to June 2010.
Another 70 consecutive patients who underwent RVA lead
implantation from January 2003 to June 2007 were used for
comparison. All patients were followed up at an outpatient clinic
in Showa University Hospital every 3–6 months after pacemaker
implantation. The primary endpoint was death caused by heart
failure (HF) and hospitalization for HF. The secondary endpoint
was all-cause mortality and hospitalization for any cause. The
following exclusion criteria were applied: (1) cumulative percent
ventricular pacing (cumulative %VP) of less than 90% or recovery
of atrioventricular conduction block, as assessed every 3–6
months in the clinic; (2) atrial ﬁbrillation; (3) left ventricular
ejection fraction (LVEF) r35%; (4) severe congestive heart failure
(CHF), deﬁned as New York Heart Association (NYHA) class III or
IV, and (5) development of acute coronary syndrome within
3 months before.2.1. Implantation procedure and determination of the pacing site
The right ventricular lead was placed via the subclavian vein. A
screw in the lead was positioned onto the right ventricular
septum using a hand-shaped stylet. A curve in the stylet was
created using the distal 5–6 cm of wire. Then, the terminal 2 cm
was bent to create a swan-neck deformity, similar to the design
suggested by Vlay [12]. The superior margin of the RVS-pacing
site can be considered as a line drawn from the superior tricuspid
annulus at the level of the His bundle. This can be represented
ﬂuoroscopically as a multipolar catheter passing through the
summit of the tricuspid valve by recording the His potential
[13] (Fig. 1A). The screw-in lead was advanced into the pulmon-
ary artery and withdrawn into the RV septum. The pacing site in
the ventricular septum was determined by ﬂuoroscopy. The
posteroanterior (PA) view was used to guide the lead into the
RVOT and mid RV (Fig. 1B). The 401 right anterior oblique (RAO)
projection was used to prevent inadvertent positioning in the
coronary sinus and great cardiac vein. Septal and free-wall sites
were determined by a leftward orientation of the lead tip in the
401 left anterior oblique (LAO) view, as proposed by Mond [14]
(Fig. 1C). The septal positioning was conﬁrmed by 2 ﬂuoroscopic
views: PA and 401 LAO.
Once the lead tip made contact with the septal wall, the screw
was deployed. The ventricular stimulation threshold at a 0.4 ms
pulse width, R-wave amplitude, and lead impedance were mea-
sured several minutes after screw deployment.His -bundle
PA viewA B LAO view
His -bundle
Septum Se
Apex
Apex
Fig. 1. Right ventricular pacing site. The dotted lines represent the boundary between t
catheter passed across the roof of the tricuspid valve. Radiographic views: posterior–ant
and the inferior lead is in the RV apex. The RV lead was placed deep in the RVA guid
patients in the RVA group had tined leads. We only used screw-in leads in 7 patientsBy contrast, a tined lead was placed at the RV apex guided by
ﬂuoroscopy in the RVA-pacing group. We used a screw-in lead in
only 7 patients in the RVA-pacing group, because a tined lead was
unable to pace the ventricle stably.
2.2. Electrocardiogram and pacemaker follow-up
ECGs were recorded daily after pacemaker implantation until
discharge and every 3–6 months at an outpatient clinic. The QRS
interval, deﬁned as the length of time from the beginning of the
pacing spike until the end of the QRS complex, was automatically
measured using FDX-6500 from recordings obtained from the
ﬁling system, FCP-2000A. The sampling rate of FDX-6500 was
1000 Hz, and the bandwidth was 0.05–100 Hz [15].
The measurement of the bipolar ventricular stimulation
threshold at a 0.4 ms pulse width and the R-wave amplitude
was performed immediately after pacemaker implantation and
every 3–6 months at the outpatient clinic. The pacing output was
programmed 2–3 times as the pacing threshold.
The cumulative %VP was determined from diagnostic data
stored on the pacemaker at each follow-up visit. When the
cumulative %VP of the patient was less than 90% or when there
was a recovery of atrioventricular conduction, the patient was
excluded from the study.
Lead dislodgement was deﬁned as movement of the lead
requiring another procedure for repositioning.
2.3. Evaluation of underlying heart disease and cardiac function
Cardiac function and underlying heart disease were assessed in
all patients by echocardiography within 1 week prior to pacing. We
also assessed cardiac function and mitral regurgitation by echo-
cardiography immediately after implantation. A cardiac electro-
physiological study was performed to determine the blocked site
within the atrioventricular conduction system. Some diagnoses
(e.g., dilated cardiomyopathy, myocarditis, and other cardiomyo-
pathies) were made after cardiac catheterization and myocardial
biopsy. HF was deﬁned by clinical symptoms, greater than NYHA
class II, or radiological evidence of pulmonary congestion.
2.4. Statistical analysis
Continuous data are expressed as the mean7standard devia-
tion. Data were compared using Student’s t-test for paired or
unpaired samples; categorical variables were analyzed with the
w2 test. The Kaplan–Meier survival techniques were used toC
ptum
he RV outﬂow tract (above) and the mid septum. This line represents a His-bundle
erior (PA) and 401 left anterior oblique (LAO). The superior lead is in the RV septum
ed by ﬂuoroscopy in the right anterior oblique (RAO) 301 projection. Most of the
in the RVA.
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pacemaker implantation to that of death or hospitalization; living
patients were censored at the last date of follow-up. All prob-
ability values were deemed statistically signiﬁcant at a level of
0.05 or below.3. Results
3.1. Patient characteristics
Patient background data are summarized in Table 1. The mean
follow-up period for patients undergoing RVS pacing was
23.5712.4 months. The average ages of the 79 patients with
RVS pacing and the 70 patients with RVA pacing were 79.778.4
years and 76.0713.0 years, respectively. The differences in age,
gender, history of HF, underlying heart disease, EF, diagnosis of
AVB on electrocardiogram, blockage site of the atrioventricular
conduction system, QRS duration, morphology of the escaped
beat, or medication at the time of pacemaker implantation
between the 2 groups were not signiﬁcant.Table 1
Patient characteristics.
Pacing site RVS pacing RVA pacing p
N 79 70
Age (mean7SD) 79.778.4 76.0713.0 ns
Sex, n (%)
Male 49(62.0) 48(68.6) ns
Female 30(38.0) 22(31.4) ns
Heart failure before implantation, n (%) 26(32.9%) 25(35.7) ns
Underlying heart disease, n (%)
Ischemic heart disease 8(10.1) 11(15.7) ns
Cardiomyopathy 7(8.9) 0(0) ns
Valvular heart disease 4(5.1) 5(7.1) ns
Ejection fraction (%) (mean7SD) 6178.6 58713.3 ns
Medications at implantation, n (%)
b-Blocker 2(2.5) 4(5.7) ns
Angiotensin-converting enzyme inhibitor 6(7.6) 8(11.4) ns
Angiotensin II receptor blockers 30(37.9) 29(41.4) ns
Furosemide 25(31.6) 28(40) ns
Spironolactone 20(25.3) 25(35.7) ns
RVS: right ventricular septal; RVA: right ventricular apical.
Fig. 2. Event-free survival curve. Only 2 patients developed congestive heart failure in
lower in patients undergoing right ventricular septal (RVS) pacing than in those under3.2. Mortality and hospitalization
Fig. 2 shows hospitalization and mortality in the RVS-pacing
group and the RVA-pacing group within 2 years after pacemaker
implantation. Fig. 2A indicates that the hospitalization from HF in
the RVS-pacing was signiﬁcantly lower than that in the RVA-
pacing group (% event free RVS: 1 year, 99% and 2 years, 98% vs.
RVA: 1 year, 85% and 2 years, 81%; po0.05). In addition, none of
the patients died from HF in the RVS-pacing group, while
4 patients died from HF in the RVA-pacing group within 2 years
after pacemaker implantation (Fig. 2B).
3.3. Pre- and postoperative QRS interval
The preoperative QRS interval was 122730 ms in the RVS-
pacing group and 129729 ms in the RVA-pacing group, which
was not signiﬁcantly different. However, the paced QRS interval
was signiﬁcantly shorter with RVS-pacing than with RVA-pacing
at different times after pacemaker implantation (RVS: immedi-
ately 157.8724.0 ms, after 3 months 157.3717.5 ms, after
6 months 153.6721.7 ms, after 12 months 153.6719.4 ms,
after 24 months 149.3724.0 ms vs. RVA: immediately 168.37
23.7 ms, after 3 months 168.7726.0 ms, after 6 months 168.07
22.8 ms, after 12 months 171.2722.3 ms, after 24 months
176.1725.5 ms; po0.05) (Fig. 3) (Table 2).the RVS-pacing group. The incidence of congestive heart failure was signiﬁcantly
going right ventricular apical RVA pacing (po0.05).
Fig. 3. Paced QRS width. The paced-QRS interval was shorter with right ventri-
cular septal (RVS) pacing than with right ventricular apical (RVA) pacing at
different times after pacemaker implantation.
Table 2
Electrocardiogram characteristics.
Pacing site RVS pacing RVA pacing p
N 79 70
Diagnosis, n (%)
II degree 7(8.9) 2(2.9) ns
Advanced 29(36.7) 18(25.7) ns
Complete 42(53.1) 49(70) ns
Block site
AH block 13(16.4) 12(17.1) ns
HH0 block 7(8.9) 8(11.4) ns
HV block 23(29.1) 23(32.9) ns
Escaped beat duration before
implantation (mean7SD)
122730 ms 129729 ms ns
Morphology of escaped beat
CRBBB 22(27.8) 28(40) ns
CLBBB 6(7.6) 10(14.3) ns
Table 3
Characteristics of patients with and without heart failure.
Developed
CHF
Non-
developed
CHF
p
n 21 128 ns
Age (mean7SD) 79.479.5 77.7711.2 ns
Sex, n (%)
Male 16(76.2) 81(63.2) ns
Female 5(23.8) 47(36.8) ns
Heart failure before implant disease 8(38.1) 43(33.5) ns
Disease
Ischemic heart 4(19.0) 15(11.7) ns
Cardiomyopathy 0(0) 7(5.5) ns
Valvular heart diseases 3(14.3) 6(4.68) ns
Ejection fraction (%) 59711.6 5979.4 ns
QRS duration before implantation 130728 ms 124729 ms ns
Pacing site
RVA 19(90.4) 51(39.8) po0.05
RVS 2(9.6) 77(60.2) po0.05
Paced QRS duration (mean7SD) 170720 ms 159723 ms p¼0.056
Diagnosis, n (%)
2 degree 0(0) 9(7.0) ns
Advanced 3(14.3) 44(34.3) ns
Complete 18(85.7) 73(58.7) ns
Block site
AH block 2(9.5) 23(18.0) ns
HH block 1(4.8) 14(10.9) ns
HV block 7(33.3) 39(30.4) ns
Morphology of escaped beats
CRBBB 9(42.9) 41(32.0) ns
CLBBB 5(23.8) 11(8.6) ns
Medications at implant, n (%)
b-Blocker 2(9.5) 5(3.9) ns
Angiotensin-converting enzyme
inhibitors
4(19.0) 10(7.8) ns
Angiotensin II receptor blockers 9(42.8) 50(39.0) ns
Furosemide 6(28.6) 47(36.7) ns
Spironolactone 6(28.6) 39(30.5) ns
CHF: congestive heart failure: RVS: right ventricular septal; RVA: right ventricular
apical.
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Within 2 years after pacemaker implantation, 21 patients
developed CHF. Background variables of the patients with CHF
are compared with the patients without CHF in Table 3. As
mentioned before, the incidence of CHF was signiﬁcantly lowerin the RVS-pacing group than in the RVA-pacing. In addition, the
paced-QRS interval immediately after pacemaker implantation
tended to be longer in patients with CHF than in the patients
without CHF (170720 ms vs. 159723 ms; p¼0.056). However,
there was no signiﬁcant difference in the other background
variables between patients with CHF and patients without CHF.
3.5. Pacing threshold, R-wave sensing, and lead impedance
There were no signiﬁcant differences in mean pacing thresh-
old, R-wave sensing, or lead impedance at the different time
points (6 months, 12 months, 18 months, and 24 months after
implantation; Table 3). The number of lead dislodgements requir-
ing surgical revision was 6 in the RVS-pacing group and 5 in the
RVA-pacing group.4. Discussion
The main ﬁnding in this study was that RVS-pacing is superior
to RVA-pacing with regard to prevention of CHF in patients with
atrioventricular block. The second ﬁnding was that patients who
developed CHF after pacemaker implantation had longer QRS
intervals than patients without CHF.
The present study demonstrated that the QRS interval mea-
sured at different times after pacemaker implantation was sig-
niﬁcantly shorter in the RVS-pacing group than in the RVA-pacing
group, which probably indicates that RVS-pacing was associated
with reduced electrical dyssynchrony. The clinical implications of
these ﬁndings were reﬂected in the decreased rate of hospitaliza-
tion for CHF and the decreased CHF-related mortality in the
RVS-pacing group when compared with the RVA-pacing group.
Furthermore, this study demonstrated that pacing parameters
(e.g., R-wave sensing and impedance) were stable over time in the
RVS pacing group and that both RVS- and RVA-pacing groups had
similarly low rates of lead dislodgement. These data indicate that
RVS pacing has long-term efﬁcacy and safety.
Previous reports have suggested that prolongation of the QRS
interval results in decreased LVEF and a higher risk of CHF [15,16].
Thus, there has been increasing interest in RV pacing sites that are
associated with more favorable physiologic function. Some stu-
dies suggest that pacing from a septal stimulation site may
produce such favorable physiologic atrioventricular conduction
[6,7]. However, the absence of deﬁnitive data showing the super-
iority of RVS-pacing over RVA-pacing has limited the adoption of
this strategy.
Durrer et al. [17] reported that ventricular depolarization
begins in the LV septum, which suggests that initiating pacing
from regions close to this area (e.g., RV septum) may produce a
physiologic contraction pattern. In contrast, the free wall of the
RV is the last zone to be depolarized. Thus, it is important to
distinguish septal positioning from other RV sites. Although a
number of studies describe RVS pacing [18,19], they do not
provide speciﬁc details regarding the position of the leads or
conﬁrmation of septal site placement. In this study, we clearly
demonstrated right ventricular septal pacing anatomically under
ﬂuoroscopy. The pacing of this site produces a narrower QRS than
the pacing of the right ventricular apex. These ﬁndings suggest
that right ventricular septal site may be more optimal than the
right ventricular apex in patients who need continuous ventri-
cular pacing. Moreover, the difference in QRS interval between
the 2 groups became signiﬁcant at different times after implanta-
tion in this study.
The negative remodeling effects of RVA-pacing may take years
to manifest. Thus, results from acute studies of RVA-pacing
cannot be generalized to outcomes in patients undergoing chronic
Table 4
Comparison of pacing threshold, R-wave amplitude, and pacing impedance.
Implant 6 months 12 months 18 months 24 months
RVS-pacing
R wave (mV) 11.875.5 11.874.4 12.476.3 11.974.8 12.476.6
Threshold (volts) 0.8870.4 0.970.4 0.8270.4 0.9070.4 0.9270.3
Impedance (O) 6807220 6107180 5367242 544718 5817334
RVA-pacing
R wave (mV) 12.676.6 15.279.2 15.6710.4 16.7711.0 15.379.1
Threshold (V) 0.5070.3 0.6870.4 0.6870.3 0.6470.3 0.6270.3
Impedance (O) 9747406 7787263 7607232 7897363 8007397
M. Kikuchi et al. / Journal of Arrhythmia 28 (2012) 214–218218pacing. Xue-Hua Z [20] reported that RVA pacing with 490%
ventricular pacing was associated with HF in 26% of patients over
a median follow-up period of 7.8 years. They also reported that an
elderly age at the time of implantation predicted new onset of HF.
Our study found that 27.2% of RVA-paced patients had HF only
2 years after implantation. The 2 studies differed in the age of
patients at the time of implantation. The mean age was 76.0713
years in our study, while it was 68.2714.9 years in that of
Xue-Hua et al. Therefore, an elderly age may predict HF after
implantation.
The use of RVS pacing has been limited by concerns regarding
procedural complication and long-term electrical performance,
such as R-wave sensing and stimulation threshold. Most studies
of RVS pacing have had a relatively small sample size, limited
follow-up duration, and include relatively few data concerning
the electrical performance and complications associated with
these septal pacing sites [21]. Lead dislodgment was the most
common adverse event in previous studies of RVS pacing, even
when RV apex pacing was employed. In order to further explore
these issues, prospective long-term comparative studies should
be conducted that include strict deﬁnitions of RVS pacing and that
exclude patients with atrial ﬁbrillation. The present study is the
ﬁrst study to meet these criteria.4.1. Study limitations
There are several limitations of this study. Firstly, it was a
retrospective analysis and was subjected to selection bias. Sec-
ondly, this study was performed in a small number of patients
within the limited facilities of our hospital. Thirdly, since implan-
tation for apical pacing was performed during the period from
January 2003 to June 2007 and implantation for septal pacing was
performed during the period from July 2007 to June 2010,
systematic cohort bias may have occurred. Therefore, the results
of this study should be interpreted with some caution. Finally,
longer-term randomized multicenter controlled studies with a
larger number of patients are needed (Table 4).5. Conclusions
RVS pacing was feasible and safe and produced more favorable
clinical outcomes than RVA pacing.Conﬂict of interest statement
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